Prostate Cancer Trial, Recruiting NCT03650595 Sponsor: University Health Network, Toronto Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT03650595
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Men between 40 and 80 years of age
  • People who have been diagnosed with low- to intermediate-risk prostate cancer, confirmed by tissue testing, with a Gleason score of 7 or less and a primary grade of 4 or less
  • People whose prostate cancer is at a clinical stage of T1c or T2 (an early stage of prostate cancer)
  • People whose MRI scan shows a suspicious area, or whose cancer has been mapped to one side of the prostate using a specific 3D scanning device
  • People whose MRI-visible tumour measures less than 20mm in size
  • People where the suspicious area seen on MRI matches the area found to be positive for cancer on biopsy
  • People with a PSA (prostate-specific antigen) blood test result below 15 ng/mL
  • People who have completed specific questionnaires about urinary and sexual health before the procedure
  • People with a life expectancy of more than 10 years, based on other health conditions unrelated to prostate cancer

Who may not be able to join:

  • People who are not considered medically suitable for a targeted prostate treatment
  • People who are unwilling or unable to provide informed consent
  • People who have received hormone therapy to lower androgen levels
  • People who have received or are currently receiving chemotherapy for prostate cancer
  • People who have previously had surgery on the prostate, including traditional, keyhole, or minimally invasive procedures such as HIFU, TUNA, RITA, microwave therapy, or cryotherapy
  • People who have had radiation therapy for prostate cancer or to the pelvic area
  • People with a history of not following medical advice or treatment plans
  • People who are unwilling or unable to complete the self-assessment questionnaires required by the study
  • People with certain prostate or bladder conditions such as chronic or acute prostatitis, neurogenic bladder, urinary tract infection, sphincter problems, or other conditions affecting normal urination
  • People who have taken part in another clinical study or received an investigational treatment within the past 90 days
  • People who cannot have an MRI scan, for example due to a pacemaker, hip replacement, severe claustrophobia, a brain aneurysm clip, or an allergy to MRI contrast dye
  • People with any other health condition or history of illness that, in the opinion of the study investigator, could affect the study results or increase risk to the patient (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sangeet Ghai, MD, Director; Biopsy Centre, Abdominal Division and Joint Department of Medical Imaging

Phone: 416-340-4800

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
29 March 2018
Est. completion
30 December 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

The proportion of study patients clinically free of clinically significant PCa (i.e. requires definitive treatment); The proportion of study patients clinically free of clinically significant PCa (i.e. requires definitive treatment)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov